Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Active, not recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Drug: PARP inhibitor
- Registration Number
- NCT04724031
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Brief Summary
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
- Detailed Description
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
- women >18 years old with advanced high grade ovarian cancer
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description One cohort PARP inhibitor women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment
- Primary Outcome Measures
Name Time Method Evaluation of Progression Free Survival 12/2022
- Secondary Outcome Measures
Name Time Method Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer 12/2021 Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer 12/2021
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PARP inhibitor efficacy in high grade ovarian cancer patients with BRCA mutations?
How do PARP inhibitors compare to standard chemotherapy in real-world outcomes for advanced ovarian cancer?
Which biomarkers are most predictive of response to olaparib or niraparib in platinum-resistant ovarian cancer?
What are the most common adverse events associated with PARP inhibitors in ovarian cancer treatment and how are they managed?
Are there combination therapies being explored with PARP inhibitors like olaparib for improved outcomes in high grade serous ovarian cancer?
Trial Locations
- Locations (1)
Adamantia Nikolaidi
🇬🇷Athens, Attiki, Greece
Adamantia Nikolaidi🇬🇷Athens, Attiki, Greece